La iniciativa "Sin Piedad" explica la història d'en David, un nen que s'està tractant d'un càncer pediàtric, un exemple d'actitud lluitadora davant la malaltia.

The money will allow research into paediatric nervous system tumours and childhood sarcomas to continue, with the aim of improving children's chances of survival and reducing the side effects of treatment.

The association makes the fifth annual donation of 52,390€ that will finance a project to study new therapies for this childhood tumor.

The BEACON clinical trial, in which Vall d'Hebron participates, has observed that adding Bevacizumab to treatment with different chemotherapy drugs reduces tumor size in a greater number of patients.

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

The research findings propose to modify the McDonald 2017 criteria, only in those in whom diagnosis using the current criteria is not possible.

The meeting, held between November 29 and December 2 in Barcelona, brought together experts and opinion leaders in the field of multiple sclerosis from around the world.

The grant program offers young researchers the opportunity to further their training in the field of multiple sclerosis.

During the last year, the collaboration between Vall d’Hebron and ZeClinics has found three nanobody candidates with potent anticancer properties in zebrafish model.

The meeting has been the meeting point of the EpSSG group dedicated to research to improve the treatment of childhood and adolescent soft tissue sarcomas.

The list identifies the most influential experts, who are among the 1% most cited in their speciality in several areas of knowledge.

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

The award is a recognition for his significant contribution to the development of research in multiple sclerosis within the Catalan Institute of Health.

The Cardiovascular Diseases and Neurovascular Diseases groups at VHIR will investigate new therapeutic strategies for heart failure, nanomedicine in stroke and the prevention of cardiovascular toxicity in the case of oncological treatments.

The funds will enable the recruitment and retention of young talent, as well as the development of a new epigenetic drug

This strategy protects almost two thirds of patients. It also reduces the waiting time between vaccination and initiation of immune suppressive treatment.

The initiative, coordinated by Dr. Pablo Velasco and Dr. Jose Luis Fuster, aims to bring innovation closer to patients and promote research projects in this disease.

The ability to be able to diagnose and differentiate both diseases as early as possible is fundamental to impact and stop the evolution of the disease before irreversible damage occurs.

This initiative has several collaborative projects with the aim of increasing knowledge about rare blood diseases and improving patient care.

The results of the study show for the first time that patients who start treatment less than six months after having the first symptoms of the disease have a slower progression and less disability than when therapy is started more than 16 months later.

The multicenter phase 1 trial has been conducted in patients aged 2 to 21 years with solid tumors unresponsive to standard treatments or in relapse.

Recently, a closing meeting was organised to wrap up the first phase of the study, which aims at grouping sufficient data of patient affected by these pathologies.

This is the most prestigious international award in the multiple sclerosis scientific and social community, given in recognition of life-long work in care, research and teaching in relation to the disease.

The finding opens the door to the development of new therapies that block neurodegeneration, beyond current treatments that focus on the inflammatory process and the control of relapses.